Abstract: Symptoms of chest pain and dysphagia are common in the adult population. Most patients initially undergo an evaluation to exclude anatomic causes (ie, esophagitis, stricture) and cardiovascular disease as the etiology of these symptoms. Patients with persistent symptoms may then be referred for specialized testing of the esophagus, including esophageal manometry. Disorders of esophageal motility, which include achalasia, diffuse esophageal spasm, nutcracker esophagus, hypertensive lower esophageal sphincter, and ineffective motility are often identified in these patients. Unfortunately, the etiology of these disorders has not been well characterized and the treatment has not been standardized. This review will briefly discuss the impact, etiology, and diagnosis of esophageal motility disorders, and then focus on the medical management of these disorders using evidence from well-designed, prospective studies, where available.
frustrated because symptoms of EMDs are nonspecific, the underlying pathophysiology has not been well characterized, and treatment options are limited. This monograph will review currently available medical therapies for EMDs. Please note that the physiology of normal esophageal motility is discussed in the monograph by Dr Goyal, whereas diagnostic testing, including esophageal manometry (EM) and high-resolution manometry, is expertly reviewed by Drs Katz and Kahrilas.
SCOPE OF THE PROBLEM Epidemiology
The prevalence of achalasia is estimated at 7.9 to 12.6 per 100,000 population, whereas the incidence of achalasia is estimated to be approximately 1 in 100,000 people. 1, 2 The prevalence of other EMDs is difficult to estimate, because large population studies have not been performed in asymptomatic individuals. One study of 1161 patients referred for the evaluation of either chest pain or dysphagia identified a manometric abnormality in 33% of patients. 3 Another study of children and young adults with chest pain found that 25% of 83 patients had a manometric abnormality uncovered by EM. 4 A more recent study found that 63% of 286 consecutive adult patients referred for EM owing to symptoms of chest pain, dysphagia, or reflux had manometric abnormalities on EM. 5 On average, it is estimated that DES is present in less than 4% of patients with chest pain.
Natural History
The natural history of EMDs is not well understood. Isolated case reports in the literature describe the apparent transition of a patient from 1 category (ie, NE) to another (ie, DES), although this may reflect normal manometric fluctuations in patients with neuromuscular dysfunction of the esophagus. Although limited, the best natural history data available involve achalasia. Ellis 6 reported on the natural history of achalasia in 85 patients first diagnosed between 1933 and 1948. Twenty-four of these patients had died at the time of follow-up (1958), 7 from carcinoma of the esophagus. Thirty-three patients were available for review and all performed a follow-up barium swallow. All patients noted progression of symptoms, and according to Dr Ellis, all had ''inevitable progression of dilation of the upper segment of the esophagus, despite treatment'' (dilation and/or cardiomyotomy). A smaller study of 14 patients who did not receive any treatment found that over a 5-year period, there was progressive dilation of the thoracic esophagus, at a mean rate of 6.1 mm/y. 7 The natural history of DES has been evaluated in 2 small studies. This is of particular interest to many physicians, owing to concerns about DES progressing to achalasia (because clinical and manometric patterns of DES often overlap with achalasia). A small prospective study of 12 patients with DES found that, over a 5-year follow-up period, only 1 patient developed achalasia. Seven of the patients continued to fit manometric criteria for DES, whereas 1 patient fit criterion for NE and 3 had normal motility studies. 8 Spencer and colleagues 9 used a questionnaire to investigate the persistence of symptoms in 72 patients with DES, NE, or a hypocontractile esophagus. They found that at follow-up (range of 3 to 10 y), most patients with DES and NE had an improvement in symptoms, although only 29% of patients with NE and 39% of patients with DES had found a specific treatment helpful. Unfortunately, follow-up manometry was not performed.
Quality of Life
Not surprisingly, it seems that patients with EMDs have a reduced quality of life (QoL). The few QoL studies performed to date have focused on patients with achalasia. Meshkinpour and colleagues 10 performed a retrospective review of 52 patients with achalasia and reported that QoL was reduced. In a small prospective study of 19 patients, Ben-Meir and colleagues 11 used the well-validated Short Form-36 questionnaire and found that the QoL of achalasia patients was reduced compared with the general population and reduced or equal to patients with gastroesophageal reflux disease (GERD). A validated questionnaire for achalasia was recently published, although no large trials to date have used it. 12 No QoL data are available for other EMDs.
Economic Impact
In contrast to other gastrointestinal disorders (ie, irritable bowel syndrome, dyspepsia, constipation, GERD), the economic impact of EMDs on the health care system has not been well characterized. Only 2 studies have attempted to address the economic costs associated with achalasia, and both of these focused on treatment costs. One study found that pneumatic dilation was less costly than intrasphincteric botulinum toxin (BTX) injection over a 10-year period. 13 A prospective, randomized trial comparing laparoscopic myotomy with pneumatic dilation in newly diagnosed achalasia patients found that costs for surgery were significantly higher than for dilation.
14 Long-term follow-up, however, was not available.
PATHOPHYSIOLOGY Overview
Health care providers interested in the history of medicine are well acquainted with the first description of the treatment of achalasia by Willis 15 in 1674 and the first case report of DES by Osgood 16 in 1889. As these disorders have been recognized clinically for centuries, it is easy to assume that the pathophysiology of these disorders is completely understood. Unfortunately, the precise pathophysiologic mechanism that leads to the development of these disorders is only (incompletely) understood for 1 disorder-achalasia. This section will briefly review what is currently known about the pathophysiology of achalasia, followed by several theories that may explain other EMDs.
Achalasia
The death of intramural inhibitory ganglion cells containing nitric oxide (NO) and vasoactive inhibitory peptide leads to the loss of normal peristalsis and the inability of the LES to relax properly during swallowing. 17 The precipitating event is unknown, although genetic, infectious, environmental, and autoimmune factors all may play a role. Other neuromuscular abnormalities seen in patients with achalasia include injury to the vagal nerve, degenerative changes in the dorsal motor nerve of the vagus, and smooth muscle hypertrophy.
Nonachalasia Motility Disorders
Although there are many theories to explain the development of EMDs, 3 in particular warrant mention. The first theory involves that of excessive contractile forces in the esophagus, which may lead to spasm or overly strong contractions. The abnormal release of acetylcholine, or an abnormal gradient of acetylcholine from the proximal to the distal esophagus, could be responsible for the prolonged, simultaneous contractions that characterize DES. The second theory involves deficient inhibitory factors in the esophagus that are unable to counteract contractile factors. For example, insufficient NO synthesis and/or release would prevent the normal damping down of contractile forces. This point was illustrated in an interesting study of 9 healthy male volunteers in which intravenous infusion of recombinant hemoglobin, a NO scavenger, produced chest discomfort in addition to spontaneous and simultaneous contractions, in a majority of volunteers. 18 The third theory is that of an imbalance or dyscoordination between contractile and inhibitory forces, although both of these factors may be present at normal levels.
Regardless of which theory is invoked, abnormalities in the nervous system are likely the underlying cause. These abnormalities could be either motor or sensory in nature, and could occur either locally within the esophagus, or more distally, either within the spinal cord or the central nervous system. As an example, 1 study of 9 patients with spastic disorders of the lower esophagus who underwent esophagomyotomy found an absence of ganglia in Auerbach plexus in patients with hypertensive LES, but normal numbers of ganglia in patients with DES and NE. 19 N-methyl-D-aspartate receptors in spinal cord neurons have been shown to play a critical role in visceral pain and hyperalgesic states, and likely also play a role in patients with EMDs. 20 Autonomic nervous system dysfunction has been found in patients with noncardiac chest pain (NCCP) and it is likely that similar abnormalities exist in patients with disordered esophageal motility.
Disordered esophageal motility may also arise owing to hypersensitivity within the esophagus. The reader is referred to the review by Dr Fass on NCCP for a complete discussion of visceral hypersensitivity and the role of acid reflux in patients with EMDs.
Finally, several studies using intraluminal ultrasound have demonstrated that the smooth muscle layers of the esophagus in patients with DES, NE, and achalasia are thicker than in normal volunteers. 21, 22 It is unknown whether thickening of the esophageal wall is the primary event in patients with EMDs, or more likely, a secondary event in response to persistent stimulation. As such, esophageal muscle wall thickness may serve as a surrogate marker for hypercontractile EMDs.
MEDICAL THERAPY Achalasia
Achalasia is defined by failure of the LES to relax properly and the progressive loss of peristalsis in the body of the esophagus. This results in failure of esophageal emptying and accumulation of material in the esophagus until the intraluminal hydrostatic pressure exceeds that of the LES, at which point the bolus passes. Clinically, this presents with progressive dysphagia to solids and liquids, regurgitation, chest pain, and weight loss. Treatment options for achalasia are currently limited to improving LES relaxation and include medical therapy, endoscopic therapy, and surgery (Tables 1, 2) .
Calcium channel blockers and nitrates have been evaluated in a number of small studies. [23] [24] [25] [26] Nifedipine (10 to 30 mg p.o. q.a.c.) decreased LES pressure by 20% to 40% compared with placebo. However, neither esophageal emptying rates 23 nor symptoms improved. 24 One study of 20 patients with mild achalasia noted persistent symptomatic improvement with sublingual (SL) nifedipine over a 6 to 18-month period, although objective tests (repeat manometry, esophageal emptying) were not performed at the end of the trial period. 25 In a randomized, 1-week, cross-over study of 15 patients comparing nifedipine (20 mg) to SL isosorbide dinitrate (5 mg), Gelfond and colleagues 27 found that nifedipine improved LES pressures more than isosorbide dinitrate, with fewer side effects. However, isosorbide improved esophageal emptying and symptoms of dysphagia to a greater degree than nifedipine. A small study of 15 patients found that a single dose of SL nitroglycerin reduced LES pressures. 28 In conclusion, side effects are generally higher with nitrates and large, long-term studies have not been conducted to document safety and efficacy. Most clinicians find that even for the occasional achalasia patient in which medications initially seem effective, the benefits are generally short-lived. For these reasons, nonpharmacologic forms of therapy are usually employed. Pneumatic dilation, in which the LES is weakened by tearing the muscle fibers, [29] [30] [31] has been used routinely since the 1960s. The most common pneumatic dilator is the Rigiflex balloon, which is passed over a guide wire 29, 30 although the long-term response to pneumatic dilation is less impressive. By 5 years, approximately 50% of patients will require further therapy. The effectiveness and durability of subsequent pneumatic dilations is considerably less than the initial treatment and alternative modalities of therapy are often required. 32, 33 Esophageal perforation is a serious potential complication, occurring in up to 10% of patients in some studies. Most experienced endoscopists believe that all patients should undergo an esophagram using watersoluble contrast to look for a leak before advancing the patient's diet.
Surgical myotomy can be performed using either the traditional open approach, or now more commonly, using minimally invasive laparoscopic or thorascopic techniques. Using the modified Heller technique (surgical longitudinal incision of the LES and the gastric cardia), 70% to 90% of patients have excellent relief of symptoms with few complications. 34, 35 The mortality rate of surgery is 0.3% and is similar to that of pneumatic dilation. Longterm follow-up suggests a sustained remission in nearly 75% to 80% of patients at 10 years, with 47% at 10 years reporting no symptoms, and 47% reporting mild to moderate symptoms. 36 Complications of surgical myotomy include the development of reflux esophagitis in 10% of patients, which can be severe. Barrett esophagus has also been noted to occur in this patient population. 37 Several studies suggest that the addition of an antireflux procedure at the time of myotomy may minimize the development of GER. In a small, prospective, randomized double-blind clinical trial of 22 patients, Heller myotomy with Dor fundoplication resulted in a decrease in GER from 47.6% to 9.1%. 38 Because of the absence of any large, prospective studies, there is no consensus in the surgical literature to date, however, on the need for antireflux surgery after myotomy.
If pneumatic dilation or surgical myotomy are not appropriate options, BTX injection into the LES has been used routinely to treat achalasia, producing short-term improvement in up to 85% of patients. 39, 40 At 6 months after BTX injection, however, only 7 of 27 (26%) patients remained in remission. The great appeal of BTX injections is its ease of use and the low risk of complications, in contrast to pneumatic dilation that carries a risk of perforation, especially in less experienced hands.
Hypercontractile Disorders
As hypercontractile disorders of the esophagus, DES, NE, and hypertensive LES are often grouped together when considering medical therapy (Tables 1, 2) . Furthermore, patients often present similarly, with complaints of dysphagia and chest pain. Commonly employed treatment options for these EMDs include calcium channel blockers, nitrates, tricycle antidepressants, smooth muscle antispasmodics, BTX, sildenafil, dietary modification, and peppermint oil. However, few large research studies are available to support the use of any of these agents.
Nitrates have long been used for spastic esophageal motility, on the basis of clinical observation that nitrates improved manometric findings and improved chest discomfort. 41, 42 However, nitrates have never been studied in a blinded, placebo-controlled trial.
In a small, randomized, double-blinded, 8-week crossover study, diltiazem (60 to 90 mg qid) significantly lowered mean distal esophageal peristaltic pressure and relieved chest pain compared with placebo in 22 patients who had NE. 43 In a 14-week cross-over study, 20 patients with NE were treated with tid nifedipine (10 to 30 mg) or placebo. 44 Nifedipine reduced LES pressure (P<0.005) and the amplitude of contractions in the distal esophagus, although no change was noted in symptoms. Two other placebo-controlled studies did not show any positive benefits of either nifedipine or diltiazem. 45, 46 Proton pump inhibitor therapy remains a main stay in the treatment of DES following a study by Crozier and colleagues, 47 which documented acid-induced esophageal spasm. Subsequent studies suggest that empiric use of a proton pump inhibitor for atypical chest pain is reasonable. Please refer to the review by Dr Fass for further details.
Two tricyclic antidepressants, trazadone and imipramine, have been shown to effectively reduce chest pain symptoms, likely through the modification of visceral sensory perception. In a 6-week, double-blind, placebocontrolled study of 29 patients with spastic esophageal disorders, trazadone (100 to 150 mg) was shown to reduce chest pain symptoms, although manometric changes were not noted. 48 Imipramine was subsequently studied in 60 patients with NCCP and normal cardiac catheterizations. In this randomized, double-blind, placebo-controlled, 3-week trial, the imipramine group had a 52% reduction in episodes of chest pain. 49 For patients with EMD who fail medical therapy, endoscopic treatment with BTX injection at the squamocolumnar junction is another therapeutic option. In an open-label study of 9 patients with DES, 100 IU of BTX were diluted in 10 mL of saline and injected in 1-mL aliquots beginning at the LES and up the tubular esophagus at an interval of 1 to 1.5 cm. 50 Symptoms improved immediately in 7 patients after the first injection. At 4 weeks, 8 of the 9 patients were in clinical remission. Four patients required reinjection between weeks 8 and 24.
Sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor, blocks the degradation of NO stimulated 3 0 5 0 -cyclic monophosphate, resulting in more prolonged smooth muscle relaxation. In a randomized, double-blind, placebocontrolled trial of 6 healthy male volunteers, sildenafil significantly reduced LES pressure and the amplitude of contractions in the distal esophagus. In an open-label study of 11 patients with DES and NE, sildenafil given once daily as needed was found to decrease both LES tone and the amplitude of contractions in the esophageal body. This resulted in significant symptom relief lasting up to 8 hours. 51 A subsequent case study involving 1 patient showed that this improvement was likely a class effect of all PDE-5 inhibitors (ie, sildenafil, tadalafil, vardanafil). 52 Many patients with hypercontractile motility disorders report that cold water can induce or exacerbate symptoms of dysphagia. On the basis of this observation, the benefit of swallowing hot water was examined. In a study of 48 patients, hot water was found to improve esophageal clearance and decrease the amplitude and duration of esophageal contractions as measured by standard EM. 53 The response to hot liquids during meals was followed for up to 6 months. Twenty-eight of the 48 patients (58%) noted some improvement in symptoms and continued the ingestion of hot liquids with meals at 6 months.
Finally, in a case series of 8 DES patients, peppermint oil led to some improvement in manometric abnormalities in patients with DES. 54 Despite the improvement in manometric findings, however, only 2 patients noted an improvement in chest pain in this uncontrolled, single-dose study.
Although the topic of NCCP is reviewed at length separately in this journal, it is important to discuss several studies at this time. Interestingly, theophylline may improve symptoms of NCCP. In a small, randomized, placebo-controlled trial, 16 patients with esophageal hypersensitivity were given intravenous theophylline or placebo and then impedance manometry was performed. Manometry demonstrated that theophylline resulted in relaxation of the esophageal wall. 55 In a second small, randomized, placebo-controlled, cross-over trial of 24 patients with functional chest pain, 55 the number of painful episodes and duration and severity of the these painful episodes were significantly reduced in 58% of patients treated with theophylline compared with 6% of patients on placebo (P<0.02). Tegaserod, a 5-HT4 receptor partial agonist (voluntarily withdrawn from the market secondary to increased cardiovascular events) has also been shown to be effective in the treatment of esophageal pain and functional heartburn. 56 Finally sertraline, a selective serotonin reuptake inhibitor, in a single site, double-blind, placebo-controlled trial of 30 patients has been shown to decrease the severity of daily NCCP. 57 
Hypocontractile Disorders
In contrast to the hypercontractile, spastic disorders, IEM is characterized by peristaltic contractions of low amplitude (<30 mm Hg) and/or <30% of contractions transmitted, resulting in ineffective esophageal transit. This diagnosis should be suspected in any patient with nonstructural dysphagia, particularly if the patient carries a concomitant diagnosis of GERD. Other etiologies for IEM include underlying myopathic, infiltrative, or endocrine disorders. IEM is often found in patients with persistent reflux symptoms, although it is not necessarily a marker of GERD. In a recent study that compared 113 patients with nonerosive reflux disease with 37 patients who had erosive esophagitis, it was noted that patients with erosive esophagitis were more likely to have IEM. 58 Unfortunately, therapeutic options that restore smooth muscle contractility in the esophagus are quite limited. However, a recent open-label study demonstrated that bethanechol, a direct-acting muscarinic receptor agonist, may improve smooth muscle function in patients with severe IEM. Multichannel intraluminal impedance and EM were performed both before and after oral administration (50 mg) of bethanechol. In this small study of 7 patients, bethanechol was associated with a statistically significant increase in esophageal contraction pressures and improved bolus transit 20 and 40 minutes after administration. 59 Larger, blinded, placebocontrolled studies will be required to confirm these preliminary results.
FUTURE THERAPIES
The prevalence of EMDs, combined with the underwhelming evidence about the effectiveness of currently medical therapy, highlights the need for more effective agents.
Strong, uncoordinated esophageal contractions characterize many patients with EMD. As noted previously, this may occur due to unopposed activity of the cholinergic nervous system. Newer anticholinergic agents that target the muscarinic type 3 receptor are now being developed (eg, zamifenacin and darifenacin). These agents help relax smooth muscle but are less likely to cause side effects (ie, increased heart rate, blurry vision, dry mouth). They have not yet been tested in patients with EMD.
Visceral hypersensitivity may be a precipitating factor in some patients with persistent chest pain. Tricyclic antidepressants improve symptoms in some patients with irritable bowel syndrome and functional abdominal pain. 60, 61 Trazadone improves chest pain symptoms in some patients, 48 although it is not known whether this represents a local or a central effect. These results provide some support to the theory that other antidepressants such as the selective serotonin reuptake inhibitors might improve symptoms of chest pain in patients with EMD, through either a central or a peripheral mechanism of action.
NO plays a critical role in the generation of symptoms in patients with EMD, especially achalasia. Oral nitrates and SL nitrates improve symptoms in some patients, as do PDE-5 inhibitors (eg, sildenafil). However, the effect of these agents is short-lived. Newer therapies may include agents with longer half-lives and injectable agents with time-release NO donors.
Corticotrophin releasing factor is a critical factor in mediating the stress response and also appears to be important in modulating visceral pain. Theoretically, corticotrophin releasing factor antagonists could improve symptoms of chest pain in patients with EMDs.
The tachykinin family includes substance P and neurokinin, in addition to lesser known peptides endokinin and hemokinin. Tachykinins play an important role in gastrointestinal motor, sensory, and secretory function. A number of animal studies have shown that antagonists to neurokinins improve pain associated with colorectal distention and irritable bowel syndrome. 62, 63 A recent study showed that a neurokinin-1 receptor antagonist did not improve esophageal hypersensitivity after acid infusion. 64 However, this experimental model of hyperalgesia is likely very different than the clinical syndromes of DES and NE. Although clinical trials with these agents in patients with EMD are ongoing, these agents may prove useful at improving symptoms of esophageal pain.
CONCLUSIONS
EMDs are prevalent and, although generally benign (excluding achalasia), cause significant distress in patients. The negative impact of EMDs on QoL and health care resources is likely high, although data are limited. Current treatment options are limited and frequently ineffective. Future research efforts should focus on understanding the pathophysiology of these disorders, which may directly translate into new therapeutic options.
